Erythropoietin modulates the neural control of hypoxic ventilation by Gassmann, M & Soliz, J
MULTI-AUTHOR REVIEW
Erythropoietin modulates the neural control of hypoxic
ventilation
Max Gassmann Æ Jorge Soliz
Received: 18 August 2009 / Accepted: 20 August 2009 / Published online: 10 September 2009
 Birkha¨user Verlag, Basel/Switzerland 2009
Abstract Numerous factors involved in general homeo-
stasis are able to modulate ventilation. Classically, this
comprises several kind of molecules, including neuro-
transmitters and steroids that are necessary for fine tuning
ventilation under different conditions such as sleep, exer-
cise, and acclimatization to high altitude. Recently,
however, we have found that erythropoietin (Epo), the
main regulator of red blood cell production, influences both
central (brainstem) and peripheral (carotid bodies) respi-
ratory centers when the organism is exposed to hypoxic
conditions. Here, we summarize the effect of Epo on the
respiratory control in mammals and highlight the potential
implication of Epo in the ventilatory acclimatization to
high altitude, as well as in the several respiratory sickness
and syndromes occurring at low and high altitude. (Part of
a multi-author review.)
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Introduction
The classical function of erythropoietin (Epo) in the
hematopoietic system is the regulation of red blood cell
production, a process that is mediated by its specific cell
surface Epo receptor (EpoR). Recently, however, Epo was
found to do far more than blood. It was observed that Epo
was not only endogenously synthesized in the fetal liver
and adult kidney [1, 2], but also in cell lines with
neuronal characteristics. Specifically, it was Sasaki and
co-authors who, in 1992, detected for the first time the
presence of Epo and functional EpoR in the neuron-like
cells PC12 and NS6 [3]. Later, we localized Epo and
Epo binding sites in specific areas of the mouse brain,
including hippocampus and cerebral cortex [4]. More
recently, we and others demonstrated in rodents and men
that Epo exerts a potent protective function upon exper-
imentally induced brain ischemia [5–10], spinal cord
ischemia and trauma [11, 12], and light-induced retinal
degeneration [7, 13, 14].
Since the neuroprotective impacts of Epo in neural tissue
have been investigated during the last decade, little is
known regarding Epo’s physiological function in the brain.
Moreover, despite the fact that Epo is a hypoxia-inducible
factor, its putative impact on respiratory control has not
been considered as a working hypothesis until recently.
Thus, the main objective of this review is to summarize the
current knowledge on the mammalian regulation of
breathing process by Epo. We provide convincing evidence
that cerebrally produced Epo is a key factor in the venti-
latory response to acute and chronic hypoxia by modulating
the respiratory centers in the brainstem. In addition, we also
review the evidence that circulating Epo in plasma controls
the peripheral carotid bodies, thus establishing the crucial
interaction between the erythropoietic system, responsible
for increasing the oxygen carrying capacity in blood, and
the neural respiratory response, that increases minute ven-
tilation. We finally discuss the putative clinical implications
of Epo in breathing diseases and the impact of Epo in the
acclimatization and de-acclimatization process to high
altitude.
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Epo regulates ventilation in hypoxia
Ventilation (VE) is the process by which O2 and CO2 are
exchanged by diffusion between the lungs and the envi-
ronment. The mammalian lungs have the capacity to
increase the ventilatory performance by a factor of 20
compared to the resting ventilation. This allows mammals
to adapt and colonize extreme environments [15], as well
as humans to permanently live at altitudes higher than
4,000 m, and to continuously challenging sports’ limits.
Taken together, investigation of factors and molecular
mechanism that permit improvement of ventilatory mech-
anism is a topic of major interest.
Hypoxia may be defined as a relative deficiency in
oxygen availability/delivery for maintaining adequate
physiological oxygen tensions, and thus results from an
imbalance between oxygen demand and supply [16]. As
such, a set of genes whose expression is regulated by cellular
oxygen tension is activated controlling the corresponding
adjustments. The hypoxia-inducible factor-1 (HIF-1) is
the most important protein regulating the physiological
homeostasis against the reduced oxygen supply [16]. HIF-1
is stabilized under hypoxic conditions conferring selectivity
to the hypoxic response. As a major transcription factor,
HIF-1 regulates the activation of more than 100 target genes
[17, 18], of which Epo is the best known one.
Epo’s impact on the brainstem respiratory centers
During the last decade, we and others have demonstrated
that Epo and its receptor (EpoR) are functionally expressed
in glial cells and neurons of mice, monkey, and humans,
implying that Epo has a much broader field of action than
so far recognized. We observed that the amount of Epo in
brain dramatically increases after hypoxic exposure of the
organism by HIF-1 stabilization [4]. The mechanisms by
which Epo exerts its function include several pathways
controlling oxygen homeostasis. Epo has been recognized
to be involved in the upregulation of oxygen-free radical
scavenger enzymes [19–21], avoiding apoptosis by main-
taining the expression of Bcl-2 and Bcl-xl [21, 22],
preventing glutamate-induced cell death [23, 24] and
activating voltage-gated channels [25, 26]. Considering
that all these processes are directly or indirectly involved in
the ventilatory acclimatization to hypoxia and corre-
sponding morphological and neurochemical regulations in
the neural respiratory network, we hypothesized a few
years ago that Epo influences the respiratory centers in the
brain. To test this hypothesis, we used a transgenic mouse
line (tg21) constitutively overexpressing human Epo only
in brain [8]. This transgenic mouse model allowed us to
test the impact of elevated brain Epo (respiratory center)
omitting the influence of elevated plasma Epo that would
probably interfere with the peripheral respiratory centers.
Both severe acute hypoxia (6% O2) and chronic hypoxic
exposure (3 days at 10% O2) showed a greater ventilatory
response in tg21 mice, compared with corresponding wild-
type (WT) control animals. Following a bilateral transection
of the carotid sinus nerves (chemodenervation) that
uncouples the brain from the carotid bodies, tg21 mice
responded to severe hypoxia with a sustained ventilation,
while chemodenervated WT animals showed life-threaten-
ing apneas, and exposure had to be stopped [27]. Because
tg21 mice express human Epo only in brain without
increasing their Epo plasma level, these results imply that
cerebral Epo is a key factor that stimulates ventilation under
conditions of reduced oxygen availability. In parallel to
these experiments, immunohistochemical analysis revealed
that EpoR is expressed in the main brainstem respiratory
centers; of note, EpoR was expressed with neurokinin-1
receptors (NK-1R) in neurons present in the pre-Bo¨tzinger
complex that are involved in the generation of the respira-
tory pattern, in the nucleus tractus solitarious (NTS), that
relays input from peripheral chemoreceptor to the central
respiratory areas, and in catecholaminergic centers in the
brainstem that are important modulators of ventilation
under hypoxic conditions [27].
Mechanisms of Epo’s impact on the brainstem
Studies using neuronal-glial cultures and mice revealed
that Epo provides neuroprotection action by activating the
Janus-tyrosine kinase 2 (JAK-2) that is linked with the
EpoR via its Box-1 motif (reviewed in [28]). JAK-2 in turn
phosphorylates, thereby activating downstream signaling
factors, such as the mitogen-activated protein (MAP)
kinases, extracellular-regulated kinase (ERK)-1/-2 [29],
phosphatidyl inositol 63 kinase (PI3k)/Akt [29, 30], Jun
kinase (JNK) [31, 32], and signal transducers and activators
of transcription (SAT)-5 [29, 33] (Fig. 1). With this in
mind, we performed western blot analysis to determine
whether the Epo signal transduction in tg21 mice was
prolonged in comparison to WT animals. We did not
observe any differences in the expression of neural JAK-2,
MAP kinase, ERK-1/-2, JNK, and AKT pathways, thus
showing that the Epo-mediated increased hypoxic ventila-
tion in tg21 mice is not related to higher activation of these
molecular neuroprotective signal transduction (note that
this result has not been previously published).
On the other hand, Epo has been recognized as a potent
factor able to modulate release of catecholamines in cells
with neuronal characteristics [34–37]. Knowing that cate-
cholamines in brainstem are important factors in the
modulation of ventilation upon hypoxic conditions
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[38–40], we used HPLC to evaluate the noradrenaline
content and the tyrosine hydroxylase (TH) activity in tg21
and WT mice. Compared to WT controls, tg21 mice show
altered catecholaminergic content in brainstem, higher
levels in pons, but lower levels in medulla. These data are
in agreement with the report showing that increased hyp-
oxic ventilation—by mean the augmentation of the
respiratory frequency—is associated with higher catechol-
amine level in pontial A5 cell group [41, 42] and with
lower catecholamine level in the medullary A1C1 and
A2C2 cell groups [43]. Thus, our results suggest that higher
Epo level modulates the catecholamine synthesis in
brainstem. Once hypoxic, this alteration affects the venti-
latory response by increasing the respiratory frequency.
In an attempt to verify our data by using WT mice, we
focused the soluble EpoR (sEpoR). In analogy to several
other members of the cytokine superfamily type I trans-
membrane proteins, EpoR is also synthesized in a soluble
form that corresponds to the extracellular domain of the
complete receptor [44–46]. The sEpoR is synthesized by
alternative splicing of EpoR mRNA and secreted to the
extracellular fluid. Once there, it binds Epo, thereby
sequestering it from the system [47–49]. We observed first
that chronic hypoxia produces a drastic downregulation of
the sEpoR in the central nervous system of WT mice [49].
In a following step, when sEpoR was chronically infused in
the nervous system of mice by a minipump, the process of
ventilatory acclimatization to chronic hypoxia (defined as a
gradual increase in ventilation to compensate for the low
O2 availability) was abolished. In parallel, the neural Epo
concentration was decreased by 50% (Fig. 2). These results
show that the neural regulation of Epo and its antagonist
sEpoR play a critical role in the central nervous system in
stabilizing the ventilatory activity and thus ensuring the
systemic oxygen delivery under low O2 conditions [49].
Taken together, our results imply that endogenous
Epo:sEpoR system in the central nervous system play a
crucial role in regulating oxygen homeostasis, thereby
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Fig. 1 Transgenic mice
overexpressing human Epo only
in brain (tg21) does not show
activation of Janus tyrosine
kinase 2 (JAK-2) or
corresponding downstream
signal factors such as signal
transducers and activators of
transcription (STAT-5),
extracellular-regulated kinase
(ERK-1/-2), jun kinase (JNK),
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Fig. 2 a Western blot analysis shows that Epo and sEpoR are
expressed in the mouse brain. b Intracerebral infusion of sEpoR
abolishes ventilatory acclimatization to chronic hypoxia. Normoxic
minute ventilation was evaluated before and after animals were
exposed chronically to hypoxia of 10% O2 during 3 days. After
acclimatization, control animals showed large increase of normoxic
ventilation. In contrast, this elevation was abolished in sEpoR-treated
mice
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ultimately contributing to the same goal as Epo in plasma,
i.e., increasing overall oxygen delivery capacity.
Plasma Epo and carotid bodies
Because oxygen is able to react fast with several other
molecules thereby producing harmful forms of reactive
oxygen species, oxygen is not stored in the organism in
large amounts. Therefore, oxygen must be continuously
supplied to settle the oxygen-dependent enzymatic reac-
tions [50]. As a result, mammals need to be equipped with
more than one mechanism to respond to the oxygen
reduction in arterial blood. The very first mechanism pro-
viding higher level of oxygen consists in the increase of
ventilation, which enlarges the overall volume of air and
thus increases the level of oxygen in the alveolus. This
quick increase of ventilation is controlled by the carotid
body. This organ senses the reduced blood oxygenation and
activates the chemoreflex pathway. The sensory informa-
tion is then relayed to brainstem neurons that in turn
modulate corresponding ventilatory adjustments. Increas-
ing ventilation is the most important hypoxic response
when mammals are acutely exposed to high altitude [51],
but it also plays a crucial role in the acclimatization process
to chronic hypoxia [52].
Despite being essential, the ventilatory system is not
sufficient to ensure adequate oxygen supply to cells and
tissues. A second important mechanism increasing the
oxygen availability consists in the augmentation of the
blood’s oxygen carrying capacity. Upon sustained hypox-
emia, Epo synthesis in the adult kidney is accelerated,
resulting in increased plasma Epo level [53, 54]. Once in the
bone marrow, Epo maintains the availability of erythrocyte
progenitor cells, promotes cell division, and increases
hemoglobin synthesis culminating in increased hematocrit
levels [55, 56]. Despite being complementary, no interac-
tion between the neural control of ventilation and the Epo-
mediated elevation of red blood cells has been described so
far. Knowing that PC12 cells, a cell line derived from rat
pheochromocitoma representing a model of peripheral
chemosensitive cells, increase their intracellular calcium
concentration, induce membrane depolarization, increase
the number of viable cells, and increase the dopamine
release and TH activity upon exposure to Epo [25, 34, 36,
37, 57], we suspected that the ventilatory and erythropoietic
response crosstalk. We postulated that higher concentration
of Epo in plasma stimulates the hypoxic ventilatory
response by interacting with carotid body cells, while ele-
vated tissue oxygenation induced by increased ventilation
will reduce the hypoxic secretion of Epo in renal cells.
The main peripheral chemoreceptors identified in small
mammals are the carotid bodies [58]. These are among the
most vascularized organs in the body (five times higher
than brain) [58], and are stimulated by the decline of
arterial oxygen partial pressure. Considering its embryonic
neural origin and its similarity with PC12 cells, we first
addressed the question whether EpoR is present in carotid
body glomus cells, as it is in brain tissue and neural-like
cells. To this end, we performed immunostaining in serial
lateral sections of the carotid body bifurcation, and used
tyrosine hydroxylase (TH) staining to identify the glomus
cells. We detected dense staining of EpoR in the carotid
body, apparently localized within islets of chemosensitive
cells [27]. This observation implies that circulatory Epo
interacts with carotid body cells, probably by binding the
EpoR. In a next step, we placed WT animals into the
plethysmograph and measured the hypoxic ventilatory
response after acute injection of 2,000 U/kg of rhEpo in the
tail vein. We observed that Epo-injected mice showed
higher respiratory frequency but lower tidal volume than
saline-injected controls when exposed to hypoxia. Con-
sidering that a glycoprotein such as Epo can hardly cross
the blood–brain barrier [59–61], these results suggest that
peripheral chemoreceptors can be activated by circulating
Epo. It is tempting to speculate that, under hypoxic expo-
sure followed by increased plasma levels, Epo stimulates
the response of carotid bodies, thus fine-tuning the neural
control of hypoxic ventilation.
Epo modulation of hypoxic ventilation is gender
dependent
Several studies on cats and rats pointed out that the carotid
bodies are one of the major sites for gender differentiation
of ventilatory control in hypoxia [62, 63], but the under-
lying mechanisms of this hormonal stimulation remain
poorly understood. Among the various neuromodulators
synthesized by glomus cells under hypoxemia, dopamine is
found at high concentration and has been recognized as a
potent inhibitory neuromodulator of carotid body chemo-
transduction [58, 64, 65]. As such, we postulated a few
years ago that sexual female hormones can modulate
hypoxic ventilation by impacting the carotid body dopa-
minergic secretion. Indeed, we found that ovarian steroids
stimulate ventilation by lowering the peripheral dopami-
nergic inhibitory drive [51]. These results are in line with
several reports showing a better capacity of women and
female mammals to adapt to hypoxia [51, 62], and to be
less susceptible to a number of hypoxia-associated issues.
Based on the fact that ovarian steroids can influence
the expression of hypoxia-inducible genes, such as renal
Epo, vascular endothelial growth factor, endotheline 1,
nitric oxide synthase, and HIF-1 [66–71], we recently
hypothesized that gender-dependent regulation of hypoxic
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ventilation is mediated by erythropoietin. To test this
hypothesis, we used a second transgenic mouse line (tg6)
showing high levels of human Epo in brain and plasma, the
latter leading to excessive erythrociatosis [8, 72]. Inter-
estingly, despite tg6 mice showing hematocrit values up to
80–90%, we found no differences in minute ventlation
between male tg6 and WT mice during exposition to
hypoxia. Nevertheless, tg6 mice showed dramatic changes
in the ventilatory pattern [73]. In contrast, when hypoxic
ventilatory response was evaluated in female tg6 animals,
we observed that minute ventilation was dramatically
increased in tg6 animals compared to corresponding WT
mice [74]. These results suggest that the gender-dependent
regulation of hypoxic ventilation imply an interaction
between Epo and sexual steroids.
In a next step, based on the notion that an intact blood–
brain barrier excludes large glycosylated molecules such as
Epo [6, 60, 61], we measured the hypoxic ventilatory
response in male and female WT mice following i.v.
injection of 2,000 U/kg of rhEpo. This experiment allowed
us to study the gender-dependent impact of Epo on carotid
bodies without the influence of cerebrally produced Epo.
While no differences were observed in male mice during
hypoxia, Epo-injected female animals underwent a tre-
mendous increase in hypoxic ventilation [74]. As such,
these results suggest that plasma Epo and sex female hor-
mones under hypoxic conditions occurs in the carotid body
cells. Note, however, that these date do not discard a
putative interaction of cerebral Epo and neurosteroids.
Finally, in an attempt to summarize the impact of central
and peripheral Epo on hypoxic ventilation, we proposed a
new model for the ventilatory response to hypoxia (Fig. 3).
Clinical implications and future research
The notion that Epo interacts with neural cells is quite
recent. Despite this short time, large efforts have been made
concerning the pathological implication of Epo as a neu-
roprotective factor [5–7, 9–14]. On the other hand, little
work has been done concerning Epo’s physiologiclal
impact. Our work clearly provides convincing evidence that
Epo, EpoR, and sEpoR play a crucial role in regulating the
systemic oxygen homeostasis in adult mice, by regulating
both central (brainstem) and peripheral (carotid bodies)
check points of ventilation in hypoxia. The clinical impli-
cations of these findings are obvious. We assume that there
is an impact of neural Epo:sEpoR in lowlanders suffering
from chronic obstructive pulmonary diseases, such as
emphysema, chronic bronchitis, and cystic fibrosis, as well
as from other types of diseases such as, polycythemia vera,
sleep apnea, and renal and liver tumor. Moreover, regarding
the increasing population permanently living at high
altitude, we postulate that plasma and cerebral Epo are
involved in the ventilatory adaptation. At present, we do not
know whether high altitude dwellers have a higher con-
centration of Epo in neural tissue, or whether neural Epo
participates in the blunted ventilation observed in acute and
chronic mountain sickness.
Of note, appropriate breathing control and optimal
oxygen supply during early life is a determinant factor for
the normal development of the respiratory control network
[75, 76], as well as for several cognitive tasks [77, 78].
Apnoea of the premature, neonatal asphyxia, or respiratory
distress syndrome in premature infants are among the most
important factors associated with impaired oxygen delivery
to the brain [19, 79]. Consequently, the implications of Epo
and sEpoR during development are of most interest. In
addition, mammalian milk contains substantial concentra-
tions of Epo, suggesting that Epo plays a pleimorphic role
in erythropoiesis, neurodevelopment, maturation of the gut,
apoptosis, and immunity in breast-fed infants [80–82]. The
expression of Epo was also found in the placenta; never-
theless, its role in this tissue remain to be elucidated.
Finally, it is interesting to mention that two different
routes of functional adaptation were naturally selected in
Tibetan and Andean high altitude natives: Tibetans have
developed increased ventilatory capacity compared to
Andean Aymaras, but complementary to this, Andeans
have generated higher hemoglobin concentrations [83].
Our data fit this observation and provide convincing
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Fig. 3 Model of ventilatory response to hypoxia showing the
contribution of cerebral and plasma Epo. During the first minutes of
hypoxia, carotid bodies sense the drop of arterial oxygen pressure thus
leading to a fast response to hypoxia. Longer exposure to hypoxia
promotes a higher secretion of Epo by the kidney. An increased level
of plasma Epo augments the oxygen carrying capacity (by gradual
increase of the hematocrit), but also contributes to the regulation of
ventilation (VE) by regulating the activity of the carotid body glomus
cells. In parallel, the level of cerebral Epo is increased in brainstem
(and decreased the level of sEpoR), thus contributing to the regulation
of central ventilation
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evidence that Epo links this adaptational mechanism. We
hypothesize that cerebral Epo, probably pushing ventila-
tory adaptation, was the option for lower energetic cost in
the evolution of Himalayan people, while renal-synthesized
Epo was the better option for the Andean population. We
are convinced that these data will contribute to our
understanding of respiratory physiology and the way to
treat the associated diseases.
Conclusion
Little is known about the physiological implication of Epo
in neural-controlled processes, and in addition, this is a
very fertile field for investigation. Our work establishing a
key implication of Epo in the neural control of hypoxic
ventilation, and the link of two complementary systems
(ventilatory and erythropoietic) in the process to augment
the general oxygen availability upon hypoxia, is very novel
and requires more investigation. Keeping in mind that Epo
is a safe drug, it will find many more applications in the
clinic. However, as only intravenous or subcutaneous drug
application is feasible in human patients, systemically
applied Epo must cross the blood–brain barrier to also be
useful in the central nervous system. In addition, an Epo
isoform able to minimize the danger of excessive eryth-
ropoiesis that could result from high levels and repeated
application of Epo needs to be developed. In other words, a
small and new erythropoietic Epo analogue is required.
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